{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:05:08Z","timestamp":1791407108284,"version":"4.3.3"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immunogenic cell death (ICD) is capable of activating the anti-tumor immune response of the organism; however, it is concurrently a complex process involving multiple factors. The specific factors that impact the occurrence of ICD remain undefined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Through cluster analysis, patient specimens retrieved from the TARGET, TCGA, and GEO AML databases were categorized into two subtypes based on the expression levels of ICD-related genes: ICD-high and ICD-low. We compared the prognostic survival outcomes, pathway enrichment analysis, and immune cell infiltration between these two subtypes. Additionally, we identified factors related to AML development from multiple databases and verified the role of these factors both in vivo and in vitro in activating the immune response during the occurrence of ICD.  <\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>In the ICD-high subtype, there was a notable increase in the abundance of immune cell populations, along with the enrichment of pathways pertinent to the activation of various immune cells. Despite these immunological enhancements, this subgroup demonstrated a poorer prognosis. This phenomenon was consistently observed across various additional AML datasets, leading us to hypothesize that elevated expression of ICD genes does not invariably correlate with a favorable prognosis. Notably, STK10 exhibited elevated expression in AML, was associated with a poor prognosis, and showed synchronous expression patterns with ICD genes. Inhibition of STK10 led to the activation of ICD and the induction of an antitumor response. Moreover, when combined with other ICD inducers, it produced a synergistic anti-tumor effect. Our results reveal the impact of STK10 on ICD and underscore its key role in initiating ICD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1451796","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:25:20Z","timestamp":1730435120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The enhancement of immunoactivity induced by immunogenic cell death through serine\/threonine kinase 10 inhibition: a potential therapeutic strategy"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaoli","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyifu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajian","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1387\/ijdb.150061pa","article-title":"Immunogenic cell death","volume":"59","author":"Garg","year":"2015","journal-title":"Int J Dev Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1177692","article-title":"Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer","volume":"5","author":"Stoll","year":"2016","journal-title":"Oncoimmunology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1795995","article-title":"Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer","volume":"9","author":"Kepp","year":"2020","journal-title":"Oncoimmunology"},{"key":"B8","article-title":"Acute myeloid leukemia","author":"Vakiti","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212556200","article-title":"Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue","volume":"278","author":"Walter","year":"2003","journal-title":"J Biol Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2605","article-title":"STK10 missense mutations associated with anti-apoptotic function","volume":"30","author":"Fukumura","year":"2013","journal-title":"Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-218","article-title":"RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing\u2019s sarcoma","volume":"9","author":"Arora","year":"2010","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5390","article-title":"An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype","volume":"6","author":"Chuang","year":"2015","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2187","article-title":"Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia","volume":"16","author":"Kharas","year":"2010","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.36","article-title":"Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform","volume":"1","author":"Shen","year":"2022","journal-title":"Imeta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1069938","article-title":"Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian Malignancies: A large-scale meta-analysis","volume":"5","author":"Garg","year":"2015","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.982720","article-title":"Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling","volume":"14","author":"Waad Sadiq","year":"2023","journal-title":"Front Immunol"},{"key":"B25","article-title":"Development and validation of immunogenic cell death-applied prediction model for esophageal carcinoma","volume":"13","author":"Wen","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.781466","article-title":"An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0616","article-title":"Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4\/IKK2\/SNARE-dependent exocytosis","volume":"8","author":"Lau","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00967-5","article-title":"Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells","volume":"22","author":"Hangai","year":"2021","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib induces immunogenic cell death in multiple myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1451796\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:25:23Z","timestamp":1730435123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1451796\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2024.1451796"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1451796","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"1451796"}}